Literature DB >> 18795920

The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.

M K A Basra1, R Fenech, R M Gatt, M S Salek, A Y Finlay.   

Abstract

BACKGROUND: The Dermatology Life Quality Index (DLQI) is one of the most widely used dermatology-specific quality of life instruments. Over the last 5 years there has been great interest in its use.
OBJECTIVES: To collect and present all information regarding the technical properties and the clinical use of the DLQI from the date it was published to the end of 2007 for use as a single source of reference.
METHODS: A detailed literature search was conducted using electronic reference databases and the DLQI library in the Department of Dermatology, Cardiff University. All publications mentioning any aspect of the DLQI, from the time of its development to the end of 2007, were identified and the data concerning the DLQI in terms of its psychometric analysis, and use in clinical trials, epidemiological studies and health services research, were extracted and tabulated with all the relevant references.
RESULTS: In total, 272 full articles which have included the DLQI were reviewed. Studies described in these articles were divided into five main categories: psychometric studies, descriptive/epidemiological studies, drug (topical and systemic) trials, clinical practice research, and therapeutic interventions. The DLQI has been used in 33 different skin conditions in 32 countries and is available in 55 languages. Psychometric aspects of the DLQI such as validity, reliability, responsiveness to change, factor structure, and minimal important difference were described in 115 studies. The DLQI has been used in 33 studies assessing the effectiveness of 14 different types of therapeutic interventions and in 37 studies evaluating nine types of clinical practice research. Sixty studies have used it alone or in parallel with other instruments as an outcome measure in clinical trials of 18 systemic drugs while 22 studies have used it in 14 different topical drug trials. The DLQI has also been used in 27 multinational studies.
CONCLUSIONS: During the last 14 years there has been a gradual increase in the international use of the DLQI. The brevity and simplicity of use of the DLQI has resulted in its popularity both in clinical practice and in research. However, there are various issues in particular regarding its unidimensionality, differential item functioning, and minimal clinically important difference, which require further research. This article should facilitate the work of potential users of the DLQI by providing a readily available source of references for different aspects of the DLQI.

Mesh:

Year:  2008        PMID: 18795920     DOI: 10.1111/j.1365-2133.2008.08832.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  157 in total

1.  CIS-based registration of quality of life in a single source approach.

Authors:  Fleur Fritz; Sonja Ständer; Bernhard Breil; Markus Riek; Martin Dugas
Journal:  BMC Med Inform Decis Mak       Date:  2011-04-21       Impact factor: 2.796

Review 2.  Efficacy of externally applied Chinese herbal drugs in treating psoriasis: a systematic review.

Authors:  Nuo Li; Yue-Qing Li; Hong-Yan Li; Wei Guo; Yan-Ping Bai
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

3.  [Dermato-epidemiology].

Authors:  C J Apfelbacher; T L Diepgen; E Weisshaar
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

4.  Discrepancies between the Dermatology Life Quality Index and utility scores.

Authors:  Fanni Rencz; Petra Baji; László Gulácsi; Sarolta Kárpáti; Márta Péntek; Adrienn Katalin Poór; Valentin Brodszky
Journal:  Qual Life Res       Date:  2015-12-18       Impact factor: 4.147

5.  The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.

Authors:  J S Kirby; L Thorlacius; B Villumsen; J R Ingram; A Garg; K B Christensen; M Butt; S Esmann; J Tan; G B E Jemec
Journal:  Br J Dermatol       Date:  2019-12-26       Impact factor: 9.302

6.  Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

Authors:  Dylan Haynes; Jennifer L Strunck; Christina A Topham; Alex G Ortega-Loayza; Gail Kent; Pamela B Cassidy; Ronghua Hu; Keith Choate; Zhiping Wang; Yuangang Liu; Teri M Greiling
Journal:  JAMA Dermatol       Date:  2020-06-01       Impact factor: 10.282

Review 7.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

8.  Health-related quality of life in morphoea.

Authors:  N K Klimas; A D Shedd; I H Bernstein; H Jacobe
Journal:  Br J Dermatol       Date:  2015-04-08       Impact factor: 9.302

9.  Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal.

Authors:  Elisabeth I Minder; Xiaoye Schneider-Yin; Christoph E Minder
Journal:  Health Qual Life Outcomes       Date:  2010-06-21       Impact factor: 3.186

10.  Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa.

Authors:  Joslyn S Kirby; Melissa Butt; Solveig Esmann; Gregor B E Jemec
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.